Gilead­'s $4.3B liv­er bet; WuXi un­der fire; Ex­sci­en­tia CEO’s ouster; Late Fri­day cell ther­a­py ap­proval; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Next week will be a short­er week than usu­al for End­points be­cause we are ob­serv­ing Pres­i­dents’ Day on Mon­day. For any break­ing news, get in touch with Rey­nald Cas­tañe­da and our Lon­don crew at rcas­tane­da@end­pointsnews.com.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER